Overcoming intractable diseases
with “Regeneration-Inducing Medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine”.

Overcoming intractable diseases
with “Regeneration-Inducing Medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine”.

IR News

December 06, 2023 Timely Disclosure Information StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation 
December 04, 2023 Timely Disclosure Information StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy 
November 16, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023 
November 16, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock 
October 27, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Change of Representative Directors 
IR News Here

NEWS Release

April 25, 2023 NEWS Release
News Release Here

Video

Video Here

We aim to bring a happy future to patients suffering from intractable diseases.

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine”.
“Regeneration-Inducing Medicine” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.

What is “Regeneration-Inducing
Medicine”?
Issues of Conventional
Cell Therapy
The Superiority of
“Regeneration-Inducing Medicine

Business

Corporate Information Investor Relations